Description: Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Home Page: www.avacta.com
Thorp Arch Estate
Wetherby,
LS23 7FA
United Kingdom
Phone:
44 1904 217 070
Officers
| Name | Title |
|---|---|
| Dr. David Alastair Smith | CEO & Exec. Director |
| Mr. Tony Gardiner | CFO, Company Sec. & Exec. Director |
| Ms. Emma Wright | Group In-House Counsel |
| Mr. Michael Vinegrad | Group Communications Director |
| Dr. Matt Johnson | Chief Scientific Officer of Diagnostics |
| Dr. Neil Bell | Chief Devel. Officer of Therapeutics |
| Dr. Fiona McLaughlin FSB, Ph.D. | Chief Scientific Officer of Therapeutics Division |
| Mr. Marc Green | Head of Product Devel. - Diagnostics |
| Gemma Wilson | Head of QA/RA - Diagnostics |
| Mr. Petros Sarantos | Head of Product Management - Diagnostics |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.6845 |
| Price-to-Sales TTM: | 49.4369 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 133 |